Cargando…

Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019

Anti-spike monoclonal antibodies emerged as effective early treatment of high-risk individuals with mild-to-moderate COVID-19. Although their clinical and safety outcomes have been reported, patient perspectives of these experimental therapies have not been evaluated. In this survey participated by...

Descripción completa

Detalles Bibliográficos
Autores principales: Razonable, Raymund R, Ganesh, Ravindra, Bishop, Rachel K, Culbertson, Tracy L, Destro Borgen, Molly, Hedin, Michelle C, Hopkins, Laura H, Jackson, Tammy A, Larsen, Jennifer J, Matoush, Jennifer A, Moehnke, Darcie E, Olson, Shelly M, Peterson, Kellie M, Rosedahl, Jordan, Philpot, Lindsey M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234828/
https://www.ncbi.nlm.nih.gov/pubmed/35769314
http://dx.doi.org/10.1177/23743735221105673
_version_ 1784736164233609216
author Razonable, Raymund R
Ganesh, Ravindra
Bishop, Rachel K
Culbertson, Tracy L
Destro Borgen, Molly
Hedin, Michelle C
Hopkins, Laura H
Jackson, Tammy A
Larsen, Jennifer J
Matoush, Jennifer A
Moehnke, Darcie E
Olson, Shelly M
Peterson, Kellie M
Rosedahl, Jordan
Philpot, Lindsey M
author_facet Razonable, Raymund R
Ganesh, Ravindra
Bishop, Rachel K
Culbertson, Tracy L
Destro Borgen, Molly
Hedin, Michelle C
Hopkins, Laura H
Jackson, Tammy A
Larsen, Jennifer J
Matoush, Jennifer A
Moehnke, Darcie E
Olson, Shelly M
Peterson, Kellie M
Rosedahl, Jordan
Philpot, Lindsey M
author_sort Razonable, Raymund R
collection PubMed
description Anti-spike monoclonal antibodies emerged as effective early treatment of high-risk individuals with mild-to-moderate COVID-19. Although their clinical and safety outcomes have been reported, patient perspectives of these experimental therapies have not been evaluated. In this survey participated by 644/2412 (26.7% response) individuals evaluated for anti-spike monoclonal antibody therapies, the majority of 523 patients who received the antibody infusion were very satisfied with their overall patient experience, the quality of care provided, and various aspects of medical care. They voiced satisfaction with the communication with providers before and during treatment, including education provided about monoclonal antibody treatment, the potential benefits and adverse effects, detailed instructions on the process of infusion, and safety protocols employed at the infusion facilities. Nearly a quarter (23.6%) of 121 patients who declined therapy indicated they would accept treatment should it be offered again. These patient perspectives may be used to guide healthcare facilities and providers in optimizing the care provided to high-risk outpatients with COVID-19.
format Online
Article
Text
id pubmed-9234828
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-92348282022-06-28 Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019 Razonable, Raymund R Ganesh, Ravindra Bishop, Rachel K Culbertson, Tracy L Destro Borgen, Molly Hedin, Michelle C Hopkins, Laura H Jackson, Tammy A Larsen, Jennifer J Matoush, Jennifer A Moehnke, Darcie E Olson, Shelly M Peterson, Kellie M Rosedahl, Jordan Philpot, Lindsey M J Patient Exp Research Article Anti-spike monoclonal antibodies emerged as effective early treatment of high-risk individuals with mild-to-moderate COVID-19. Although their clinical and safety outcomes have been reported, patient perspectives of these experimental therapies have not been evaluated. In this survey participated by 644/2412 (26.7% response) individuals evaluated for anti-spike monoclonal antibody therapies, the majority of 523 patients who received the antibody infusion were very satisfied with their overall patient experience, the quality of care provided, and various aspects of medical care. They voiced satisfaction with the communication with providers before and during treatment, including education provided about monoclonal antibody treatment, the potential benefits and adverse effects, detailed instructions on the process of infusion, and safety protocols employed at the infusion facilities. Nearly a quarter (23.6%) of 121 patients who declined therapy indicated they would accept treatment should it be offered again. These patient perspectives may be used to guide healthcare facilities and providers in optimizing the care provided to high-risk outpatients with COVID-19. SAGE Publications 2022-06-23 /pmc/articles/PMC9234828/ /pubmed/35769314 http://dx.doi.org/10.1177/23743735221105673 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Research Article
Razonable, Raymund R
Ganesh, Ravindra
Bishop, Rachel K
Culbertson, Tracy L
Destro Borgen, Molly
Hedin, Michelle C
Hopkins, Laura H
Jackson, Tammy A
Larsen, Jennifer J
Matoush, Jennifer A
Moehnke, Darcie E
Olson, Shelly M
Peterson, Kellie M
Rosedahl, Jordan
Philpot, Lindsey M
Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019
title Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019
title_full Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019
title_fullStr Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019
title_full_unstemmed Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019
title_short Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019
title_sort patient perspectives on anti-spike monoclonal antibody therapy for mild to moderate coronavirus disease-2019
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234828/
https://www.ncbi.nlm.nih.gov/pubmed/35769314
http://dx.doi.org/10.1177/23743735221105673
work_keys_str_mv AT razonableraymundr patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019
AT ganeshravindra patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019
AT bishoprachelk patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019
AT culbertsontracyl patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019
AT destroborgenmolly patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019
AT hedinmichellec patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019
AT hopkinslaurah patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019
AT jacksontammya patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019
AT larsenjenniferj patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019
AT matoushjennifera patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019
AT moehnkedarciee patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019
AT olsonshellym patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019
AT petersonkelliem patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019
AT rosedahljordan patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019
AT philpotlindseym patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019